These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Recent progress in drug development for fibrodysplasia ossificans progressiva. Meng X, Wang H, Hao J. Mol Cell Biochem; 2022 Oct; 477(10):2327-2334. PubMed ID: 35536530 [Abstract] [Full Text] [Related]
14. ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation. van Dinther M, Visser N, de Gorter DJ, Doorn J, Goumans MJ, de Boer J, ten Dijke P. J Bone Miner Res; 2010 Jun; 25(6):1208-15. PubMed ID: 19929436 [Abstract] [Full Text] [Related]
18. Hematopoietic stem-cell contribution to ectopic skeletogenesis. Kaplan FS, Glaser DL, Shore EM, Pignolo RJ, Xu M, Zhang Y, Senitzer D, Forman SJ, Emerson SG. J Bone Joint Surg Am; 2007 Feb; 89(2):347-57. PubMed ID: 17272450 [Abstract] [Full Text] [Related]
19. iMSC-mediated delivery of ACVR2B-Fc fusion protein reduces heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva. Gao P, Inada Y, Hotta A, Sakurai H, Ikeya M. Stem Cell Res Ther; 2024 Mar 18; 15(1):83. PubMed ID: 38500216 [Abstract] [Full Text] [Related]
20. Twists in the fibrodysplasia ossificans progressiva story challenge and expand our understanding of BMP biology. Collins MT. J Clin Invest; 2022 Jun 15; 132(12):. PubMed ID: 35703179 [Abstract] [Full Text] [Related] Page: [Next] [New Search]